RPGLIFEPharmaceuticals
RPG Life Sciences Ltd — Cash Flow Statement
₹1857.70
-2.96%
RPG Life Sciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 41.83 Cr | 25.13 Cr | 58.09 Cr | 40.80 Cr | — |
| Repayment Of Debt | 0.00 | -0.01 Cr | -0.27 Cr | -0.42 Cr | — |
| Capital Expenditure | -36.03 Cr | -69.23 Cr | -32.73 Cr | -23.95 Cr | — |
| End Cash Position | 28.70 Cr | 19.72 Cr | 24.82 Cr | 56.94 Cr | — |
| Beginning Cash Position | 19.72 Cr | 24.82 Cr | 56.94 Cr | 40.36 Cr | — |
| Changes In Cash | 8.98 Cr | -5.10 Cr | -32.11 Cr | 16.58 Cr | — |
| Financing Cash Flow | -27.08 Cr | -20.31 Cr | -17.12 Cr | -13.51 Cr | — |
| Interest Paid Cff | -0.62 Cr | -0.45 Cr | -0.31 Cr | -0.52 Cr | — |
| Cash Dividends Paid | -26.46 Cr | -19.85 Cr | -15.88 Cr | -11.91 Cr | — |
| Common Stock Dividend Paid | -26.46 Cr | -19.85 Cr | -15.88 Cr | -11.91 Cr | — |
| Net Issuance Payments Of Debt | 0.00 | -0.01 Cr | -0.28 Cr | -0.42 Cr | — |
| Net Long Term Debt Issuance | 0.00 | -0.01 Cr | -0.01 Cr | -0.11 Cr | — |
| Long Term Debt Payments | 0.00 | -0.01 Cr | 0.00 | -0.11 Cr | — |
| Investing Cash Flow | -41.80 Cr | -79.15 Cr | -105.81 Cr | -34.66 Cr | — |
| Net Other Investing Changes | 4.50 Cr | 15.47 Cr | -18.90 Cr | -0.07 Cr | — |
| Interest Received Cfi | 3.21 Cr | 1.42 Cr | 2.73 Cr | 1.33 Cr | — |
| Net Investment Purchase And Sale | -122.95 Cr | -11.49 Cr | -75.89 Cr | -11.97 Cr | — |
| Sale Of Investment | 47.71 Cr | 33.02 Cr | 0.00 | 0.89 Cr | — |
| Purchase Of Investment | -170.66 Cr | -44.51 Cr | -75.89 Cr | -12.86 Cr | — |
| Net PPE Purchase And Sale | 73.44 Cr | -69.08 Cr | -32.65 Cr | -23.95 Cr | — |
| Sale Of PPE | 109.47 Cr | 0.15 Cr | 0.08 Cr | 0.00 | — |
| Purchase Of PPE | -36.03 Cr | -69.23 Cr | -32.73 Cr | -23.95 Cr | — |
| Capital Expenditure Reported | -36.03 Cr | -69.23 Cr | — | — | -8.51 Cr |
| Operating Cash Flow | 77.86 Cr | 94.36 Cr | 90.82 Cr | 64.75 Cr | — |
| Taxes Refund Paid | -52.75 Cr | -29.31 Cr | -25.23 Cr | -18.85 Cr | — |
| Change In Working Capital | -26.05 Cr | -7.09 Cr | 11.05 Cr | -3.11 Cr | — |
| Change In Other Current Liabilities | -14.38 Cr | 12.41 Cr | 6.02 Cr | -0.44 Cr | — |
| Change In Other Current Assets | 5.34 Cr | -5.26 Cr | 4.57 Cr | -0.90 Cr | — |
| Change In Payable | 9.54 Cr | 6.33 Cr | 19.26 Cr | -1.91 Cr | — |
| Change In Inventory | 6.19 Cr | -5.95 Cr | -12.06 Cr | -24.66 Cr | — |
| Change In Receivables | -35.73 Cr | -14.23 Cr | -5.48 Cr | 24.71 Cr | — |
| Other Non Cash Items | -86.44 Cr | -0.97 Cr | -2.42 Cr | -0.81 Cr | — |
| Provisionand Write Offof Assets | -2.77 Cr | 2.70 Cr | 0.43 Cr | 0.05 Cr | — |
| Depreciation And Amortization | 21.43 Cr | 17.07 Cr | 15.50 Cr | 15.66 Cr | — |
| Amortization Cash Flow | 6.60 Cr | 6.66 Cr | 6.79 Cr | 6.83 Cr | — |
| Depreciation | 14.83 Cr | 10.41 Cr | 8.71 Cr | 8.83 Cr | — |
| Gain Loss On Investment Securities | -6.96 Cr | -5.77 Cr | -1.44 Cr | -0.89 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.28 Cr | -0.10 Cr | 0.46 Cr | -0.47 Cr | — |
| Gain Loss On Sale Of PPE | -1.20 Cr | -0.01 Cr | 0.78 Cr | 0.00 | — |
| Net Income From Continuing Operations | 232.88 Cr | 117.84 Cr | 91.68 Cr | 73.17 Cr | — |
| Net Short Term Debt Issuance | — | 0.00 | -0.27 Cr | -0.31 Cr | -4.60 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | -0.01 Cr | — | — |
| Net Other Financing Charges | — | — | -0.01 Cr | — | — |
| Short Term Debt Payments | — | — | -0.27 Cr | -0.31 Cr | -4.60 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on RPG Life Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.